{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:37:07Z","timestamp":1793507827595,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"A Menarini Pharmaceutical Industries Riunite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108535","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:09:53Z","timestamp":1789430993000},"page":"108535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u00c1.","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Sanchez","family":"Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Okines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108535_bib1","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108535_bib3","author":"Gennari"},{"key":"10.1016\/j.esmoop.2026.108535_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2026.108535_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108535_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort","volume":"7","author":"Iams","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2026.108535_bib9","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108535_bib10","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108535_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-25-3033","article-title":"Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer","volume":"32","author":"Lloyd","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108535_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1078-0432.CCR-25-3040","article-title":"Real-world outcomes of elacestrant in ER+, HER2-, ESR1-mutant metastatic breast cancer","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2026.108535_bib13","article-title":"Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group","volume":"38","author":"Walker","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108535_bib14","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108535_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2217\/fon-2022-0616","article-title":"Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors","volume":"19","author":"Agapow","year":"2023","journal-title":"Future Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108535_bib16","volume":"82","author":"Turner","year":"2022","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108535_bib17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2023.41.16_suppl.1078","article-title":"Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: analysis of all 3 cohorts of the BYLieve study","volume":"41","author":"Chia","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108535_bib18","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108535_bib19","article-title":"Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR+\/HER2\u2013 advanced breast cancer: subgroup analyses from the phase 3 CAPItello-291 trial","volume":"8","author":"Oliveira","year":"2023","journal-title":"ESMO Open"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108535_bib20","volume":"43","author":"Chia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108535_bib21","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108535_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13058-021-01394-y","article-title":"Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy","volume":"23","author":"Rozenblit","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108535_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-024-07415-6","article-title":"First- vs second-line CDK 4\/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting","volume":"208","author":"Kimmick","year":"2024","journal-title":"Breast Cancer Res Treat"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:43Z","timestamp":1792712443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926024804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926024804"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108535","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108535"}}